Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) Interest & Investment Income (2023 - 2025)

NewAmsterdam Pharma's Interest & Investment Income history spans 3 years, with the latest figure at $6.5 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 44.33% year-over-year to $6.5 million; the TTM value through Dec 2025 reached $27.6 million, up 63.45%, while the annual FY2025 figure was $27.6 million, 63.45% up from the prior year.
  • Interest & Investment Income for Q4 2025 was $6.5 million at NewAmsterdam Pharma, down from $6.7 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $7.4 million in Q1 2025 and bottomed at $943000.0 in Q1 2023.
  • The 3-year median for Interest & Investment Income is $4.5 million (2023), against an average of $4.6 million.
  • The largest YoY upside for Interest & Investment Income was 226.94% in 2024 against a maximum downside of 5.57% in 2024.
  • A 3-year view of Interest & Investment Income shows it stood at $2.7 million in 2023, then surged by 68.1% to $4.5 million in 2024, then skyrocketed by 44.33% to $6.5 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Interest & Investment Income are $6.5 million (Q4 2025), $6.7 million (Q3 2025), and $7.1 million (Q2 2025).